Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Other Operating Expenses (2019 - 2025)

Coherus Oncology's Other Operating Expenses history spans 8 years, with the latest figure at $4.0 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 431.01% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $13.8 million, down 55.89%, while the annual FY2025 figure was $13.8 million, 58.29% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $4.0 million at Coherus Oncology, up from $3.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $199.5 million in Q1 2021 and bottomed at -$175.3 million in Q2 2021.
  • The 5-year median for Other Operating Expenses is $6.7 million (2022), against an average of $3.8 million.
  • The largest YoY upside for Other Operating Expenses was 2810.33% in 2021 against a maximum downside of 1828.93% in 2021.
  • A 5-year view of Other Operating Expenses shows it stood at $12.1 million in 2021, then plummeted by 745.25% to -$78.1 million in 2022, then dropped by 1.99% to -$79.7 million in 2023, then soared by 98.47% to -$1.2 million in 2024, then soared by 431.01% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Other Operating Expenses are $4.0 million (Q4 2025), $3.7 million (Q3 2025), and $3.4 million (Q2 2025).